Idorsia Drug Patent Portfolio

Idorsia owns 2 orange book drugs protected by 8 US patents Given below is the list of Idorsia's drug patents along with their expiration dates.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US11680058 Crystalline forms of a 4-pyrimidinesulfamide derivative aprocitentan 26 Jul, 2038
Active
US11787782 Combinations of a 4-pyrimidinesulfamide derivative with active ingredients for the treatment of endothelin related diseases 02 Mar, 2038
Active
US10919881 Crystalline forms of a 4-pyrimidinesulfamide derivative aprocitentan 26 Feb, 2038
Active
US11174247 Combinations of a 4-pyrimidinesulfamide derivative with active ingredients for the treatment of endothelin related diseases 06 Nov, 2037
Active
US10023560 Crystalline salt form of (S)-(2-(6 chloro-7-methyl-1H-benzo[d]imidazol-2-yl)-2-methylpyrrolidin-1-yl)(5-methoxy-2-(2H-1,2,3-triazol-2-yl)phenyl)methanone as orexin receptor antagonist 02 Dec, 2034
Active
US9790208 Crystalline salt form of (S)-(2-(6-chloro-7-methyl-1H-benzo[d]imidazol-2-yl)-2-methylpyrrolidin-1-yl)(5-methoxy-2-(2H-1,2,3-triazol-2-yl)phenyl)methanone as orexin receptor antagonist 02 Dec, 2034
Active
US9732075 Benzimidazole-proline derivatives 12 Jun, 2033
Active
US8324232 4-pyrimidinesulfamide derivative 21 Sep, 2029
Active


Given below is the list of recent legal activities going on the following drug patents of Idorsia.

Activity Date Patent Number
Patent litigations
Mail Pub Notice re 312 amendment 31 May, 2024 US9732075
Email Notification 31 May, 2024 US9732075
POST ISSUE OTHER COMMUNICATION TO APPLICANT- CERTIFICATE OF CORRECTION 28 May, 2024 US9732075
Initial letter Re: PTE Application to regulating agency 16 May, 2024 US8324232
Patent Term Extension Application under 35 USC 156 Filed 10 May, 2024 US8324232
Second letter to regulating agency to determine regulatory review period 23 Oct, 2023 US9732075
Recordation of Patent eGrant 17 Oct, 2023 US11787782
Mail Patent eGrant Notification 17 Oct, 2023 US11787782
Email Notification 17 Oct, 2023 US11787782
Recordation of Patent Grant Mailed 17 Oct, 2023 US11787782
Patent eGrant Notification 17 Oct, 2023 US11787782
Patent Issue Date Used in PTA Calculation 17 Oct, 2023 US11787782
Email Notification 28 Sep, 2023 US11787782
Letter from FDA or Dept of Agriculture re PTE application 28 Sep, 2023 US9732075
Issue Notification Mailed 27 Sep, 2023 US11787782


Idorsia's Family Patents

Idorsia drugs have patent protection in a total of 35 countries. It's US patent count contributes only to 8.5% of its total global patent coverage. 2 countries have all of their patents expired or invalidated which has opened up potential generic launch opportunities in these countries. Click below to unlock the full patent family tree.

Family Patents



Idorsia Drug List

Given below is the complete list of Idorsia's drugs and the patents protecting them.


1. Quviviq

Quviviq is protected by 3 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US10023560 Crystalline salt form of (S)-(2-(6 chloro-7-methyl-1H-benzo[d]imidazol-2-yl)-2-methylpyrrolidin-1-yl)(5-methoxy-2-(2H-1,2,3-triazol-2-yl)phenyl)methanone as orexin receptor antagonist 02 Dec, 2034
(10 years from now)
Active
US9790208 Crystalline salt form of (S)-(2-(6-chloro-7-methyl-1H-benzo[d]imidazol-2-yl)-2-methylpyrrolidin-1-yl)(5-methoxy-2-(2H-1,2,3-triazol-2-yl)phenyl)methanone as orexin receptor antagonist 02 Dec, 2034
(10 years from now)
Active
US9732075 Benzimidazole-proline derivatives 12 Jun, 2033
(8 years from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Quviviq's drug page


2. Tryvio

Tryvio is protected by 5 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US11680058 Crystalline forms of a 4-pyrimidinesulfamide derivative aprocitentan 26 Jul, 2038
(13 years from now)
Active
US11787782 Combinations of a 4-pyrimidinesulfamide derivative with active ingredients for the treatment of endothelin related diseases 02 Mar, 2038
(13 years from now)
Active
US10919881 Crystalline forms of a 4-pyrimidinesulfamide derivative aprocitentan 26 Feb, 2038
(13 years from now)
Active
US11174247 Combinations of a 4-pyrimidinesulfamide derivative with active ingredients for the treatment of endothelin related diseases 06 Nov, 2037
(12 years from now)
Active
US8324232 4-pyrimidinesulfamide derivative 21 Sep, 2029
(4 years from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Tryvio's drug page


Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List